[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"distant-metastasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:distant-metastasis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100611033","phase-3-pd-1-inhibitor-plus-chemotherapy-followed-by-immediate-versus-salvage-locoregional-radiotherapy-in-de-novo-metastatic-npc-100611033",false,"NCT07235319","PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC","A Multicenter, Open-Label, Randomized Phase III Non-Inferiority Trial of PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Age 18-70 years, any gender.\n2. Histologically confirmed differentiated non-keratinizing carcinoma or undifferentiated non-keratinizing carcinoma by tissue biopsy, with radiologically detectable metastatic lesions. Pathological confirmation of metastatic lesions is recommended but not mandatory.\n3. ECOG performance status 0-1.\n4. Stage IV NPC according to the 9th edition of the UICC\u002FAJCC staging system.\n5. No prior anti-tumor treatment for NPC (radiotherapy, chemotherapy, surgery, etc.).\n6. Expected survival ≥ 3 months.\n7. At least one measurable lesion per RECIST v1.1.\n8. Achieved complete response (CR) or partial response (PR) after 4-6 cycles of chemotherapy plus PD-1 inhibitor therapy.\n9. Adequate organ function within 14 days before first dose, defined as:\n\n   Hematology：Hemoglobin ≥ 90 g\u002FL，ANC ≥ 1.5 × 10⁹\u002FL，Platelet count ≥ 100 × 10⁹\u002FL Renal Function：Creatinine ≤ 1.5 × ULN, or creatinine clearance (CrCl) \u002F eGFR ≥ 60 mL\u002Fmin Liver Function：Total bilirubin ≤ 1.5 × ULN，AST and ALT ≤ 2.5 × ULN, or ≤ 5 × ULN in the presence of liver metastases\n10. INR or PT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range，aPTT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range\n\nExclusion Criteria:\n\n1. Prior anti-tumor therapy for nasopharyngeal carcinoma, including radiotherapy, chemotherapy, surgery, or immunotherapy.\n2. Prior treatment with PD-1\u002FPD-L1 or CTLA-4 inhibitors.\n3. Presence of uncontrolled or symptomatic central nervous system (CNS) metastases.\n4. History of other malignancies within the past 5 years, except adequately treated basal cell carcinoma, squamous cell skin cancer, or in-situ cervical cancer.\n5. Active autoimmune disease or history of autoimmune disease requiring systemic treatment (e.g., corticosteroids, immunosuppressants) within the past 2 years, except for stable hypothyroidism, type 1 diabetes mellitus, or resolved childhood asthma\u002Fatopy.\n6. Known history of active pulmonary tuberculosis (TB). Suspected active TB must be excluded by chest X-ray, sputum examination, and assessment of clinical signs and symptoms.\n7. Hepatitis B: HBsAg positive with peripheral blood HBV DNA ≥ 1000 copies\u002FmL\n8. Hepatitis C: HCV antibody positive, eligible only if HCV RNA is negative\n9. HIV infection\n10. Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, myocardial infarction within 6 months, congestive heart failure ≥ NYHA class II, or serious arrhythmia).\n11. Interstitial lung disease, non-infectious pneumonitis, or history of ≥ grade 2 pneumonitis.\n12. Major surgery within 4 weeks before enrollment, or unhealed surgical wound.\n13. Pregnant or breastfeeding women, or those planning pregnancy during the study period.\n14. Known allergy or hypersensitivity to study drugs or their excipients.\n15. Any condition that, in the investigator's judgment, would interfere with trial participation or interpretation of results.","ALL","18 Years","70 Years",{"count":20,"type":21},260,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This phase III randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus salvage locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma. The study aims to evaluate whether salvage locoregional radiotherapy is non-inferior to immediate radiotherapy following PD-1 inhibitor plus GP in de novo metastatic NPC, with potential for reduced toxicity.",[27,28],"Nasopharangeal Cancer","Distant Metastasis",[30],"Locoregional radiotherapy","RECRUITING","2025-11-17",{"date":34,"type":35},"2025-11-19","ACTUAL",{"date":37,"type":21},"2025-11-20",{"date":39,"type":21},"2034-11-20",{"name":41,"class":42},"Sun Yat-sen University","OTHER",5,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100579981","development-and-validation-of-a-deep-learning-model-to-predict-distant-metastases-in-nasopharyngeal-carcinoma-using-whole-slide-imaging-and-mri-100579981","NCT06831357","Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI","Development and Multicenter Validation of a Deep Learning Model Based on Whole Slide Imaging and Magnetic Resonance Imaging of the Nasopharynx and Lymph Nodes to Predict Distant Metastases at Diagnosis in Nasopharyngeal Carcinoma","Inclusion Criteria:\n\nA. The primary lesion was pathologically confirmed as nasopharyngeal carcinoma (WHO classification is I, II and III); B. The stage was T3-4 or N2-3, and the nasopharynx + neck MRI plain scan and enhanced scan were performed to confirm the nasopharyngeal and cervical lymph node lesions, and PET\u002FCT or conventional examination (chest CT plain scan + enhanced scan, upper abdominal CT or MRI plain scan + enhanced scan or abdominal color Doppler ultrasound or ultrasound angiography, and whole body bone imaging) was performed to screen for distant metastases.\n\nExclusion Criteria:\n\nPrevious history of other malignant tumors (such as other head and neck squamous cell carcinomas, thyroid cancer, breast cancer, esophageal cancer, etc.).",{"count":52,"type":21},500,"OBSERVATIONAL","An AI model was developed to predict the likelihood of distant metastasis in patients with nasopharyngeal cancer based on pathology slides and MRI scans of the primary tumor. The model was validated using data from multiple centers. It was then applied to patients with advanced stages who were recommended to undergo PET\u002FCT scans based on the NCCN or CSCO guidelines. This AI model can accurately screen patients with high risk of distant metastasis at the time of initial diagnosis to receive PET\u002FCT, avoid excessive examination of patients with low risk of distant metastasis, save medical resources and reduce the economic burden on patients.",[56,28],"Nasopharyngeal Cancinoma (NPC)",[56,28,58,59,60,61],"PET\u002FCT","MRI","whole slide imaging","deep learning model","2025-02-21",{"date":64,"type":35},"2025-02-25",{"date":66,"type":21},"2025-02-15",{"date":68,"type":21},"2026-12-31",{"name":41,"class":42},2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100523919","a-predictive-model-for-early-metastasis-in-cervical-cancer-patients-after-radiotherapy-100523919","NCT06101966","A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy","A Novel Predictive Model and Risk Stratification for Early Metastasis in Cervical Cancer Patients After Radiotherapy","Inclusion Criteria:\n\n* patients confirmed as cervical cancer by biopsies and treated with radiotherapy were initially enrolled\n\nExclusion Criteria:\n\n* (1) patients treated with surgery. (2) patient received incomplete treatment somewhere else. (3) patients with cancer history. (4) patients with pelvic surgery history. (5) patients without complete pre-treatment medical information. (6) patients with unfinished radical radiotherapy. (7) patients suffered from metastasis within 3 months after radiotherapy. (8) patients without complete 1-year follow-up materials","FEMALE","20 Years","85 Years",{"count":52,"type":21},"This study aims to help to screen out appropriate cases for consolidation therapy and more intensive follow up.",[84,85,28,86,87],"Cervical Cancer","Radiotherapy","Prognostic Model","Risk Factor","NOT_YET_RECRUITING","2023-10-21",{"date":91,"type":35},"2023-10-26",{"date":93,"type":21},"2023-12-01",{"date":95,"type":21},"2027-12-01",{"name":97,"class":98},"Fujian Cancer Hospital","OTHER_GOV",1]